Recursion Pharmaceuticals, Inc.
NASDAQRXRX short interest squeeze risk escalates: utilization hits 91.39%, highest level in 52 weeks, while 35.4% of free float remains shorted.
RXRX ends the week with a contradiction at its core: short interest near multi-month highs, a lending market that has run completely dry, and options traders piling into calls rather than puts. The lending picture…
Three signals converged on RXRX Tuesday. Availability has hit zero. Short interest sits at a multi-month high. And options traders are piling into calls, not puts. The signals point in different directions — and that…
Snapshot as of 15 Aug 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RXRX — free to start on ORTEX.
Sign up for free →Open RXRX on ORTEX